Selected articles
Articles for label Vaníček Jiří are displayed.. Show all articles
Epithelial tumors of the thymus and diagnostic options
05/2020 MUDr. Vladimír Červeňák, MUDr. Zdeněk Chovanec, Ph.D., MUDr. Alena Berková, Ph.D., doc. MUDr. Jiří Vaníček, Ph.D., MUDr. Tomáš Hanslík, MUDr. Sabina Svobodová, MUDr. Robert Novák
Epithelial tumors are the most common tumors of the thymus. This group of tumors includes thymomas and thymic carcinoma and these tumors are very rare, although they are among the most common tumors of the anterior mediastinum in adults. The thymus is an organ of the immune system that can be routinely monitored by various chest examination methods. We encounter it more in children, but it is no exception in adults either. The problem in adults is its variable appearance, as it goes through the process of involution. Involution is support by the corticosteroids during excessive stress. Likewise, these conditions can change its shape and size. The basics of embryology, anatomy together with knowledge of imaging methods, are a necessary condition for accurate diagnosis of benign and malignant thyroid tumors. Only the correct identification of these pathologies allows you to choose the appropriate method of therapy.
ENTIRE ARTICLE
Epithelial tumors are the most common tumors of the thymus. This group of tumors includes thymomas and thymic carcinoma and these tumors are very rare, although they are among the most common tumors of the anterior mediastinum in adults. The thymus is an organ of the immune system that can be routinely monitored by various chest examination methods. We encounter it more in children, but it is no exception in adults either. The problem in adults is its variable appearance, as it goes through the process of involution. Involution is support by the corticosteroids during excessive stress. Likewise, these conditions can change its shape and size. The basics of embryology, anatomy together with knowledge of imaging methods, are a necessary condition for accurate diagnosis of benign and malignant thyroid tumors. Only the correct identification of these pathologies allows you to choose the appropriate method of therapy.
Cabozantinib in the treatment of patients with renal cell carcinoma
01/2019 MUDr. Jana Katolická, Ph.D.; MUDr. Jiří Vaníček, Ph.D.
Cabozantinib is a novel multitargeted tyrosine kinase inhibitor that improved progression-free survival and overall survival in patients with advanced renal cell carcinoma after one or more prior vascular endothelial growth factor receptor targeted therapies. The safety profile of cabozantinib is acceptable.
ENTIRE ARTICLE
Cabozantinib is a novel multitargeted tyrosine kinase inhibitor that improved progression-free survival and overall survival in patients with advanced renal cell carcinoma after one or more prior vascular endothelial growth factor receptor targeted therapies. The safety profile of cabozantinib is acceptable.
Clear cell renal carcinoma treated with cabozantinib in the METEOR study – case study
05/2017 MUDr. Jana Katolická, Ph.D., MUDr. Sabina Svobodová, MUDr. Jiří Vaniček, Ph.D., Mgr. Pavlína Prosecká
Targeted treatment is currently a standard therapeutic method for metastatic clear cell renal carcinoma. Cabozantinib is an oral tyrosine kinase inhibitor including MET, VEGFR, and AXL. In a randomized phase III METEOR study, prolongation of survival in patients following prior VEGFR treatment with tyrosine kinase inhibitors has been demonstrated.
ENTIRE ARTICLE
Targeted treatment is currently a standard therapeutic method for metastatic clear cell renal carcinoma. Cabozantinib is an oral tyrosine kinase inhibitor including MET, VEGFR, and AXL. In a randomized phase III METEOR study, prolongation of survival in patients following prior VEGFR treatment with tyrosine kinase inhibitors has been demonstrated.